Drugs / Abelmoschus manihot
Abelmoschus manihot
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03016832 | Jan 2017 → May 2018 | diabetic kidney disease | Jiangsu Famous Medical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02231125 | Sep 2014 → Jul 2016 | IgA glomerulonephritis | Chen Xiangmei | Unknown | No outcome recorded |
| Phase 4 | NCT02231138 | Sep 2014 → Jan 2016 | chronic kidney disease | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Abelmoschus manihot | “Efficacy of Combined Abelmoschus manihot and Irbesartan for Reduction of” PMID 35613364 ↗ Jul 2022 |
| Modality | Traditional medicine (herbal / TCM) | “Huangkui Capsule is a single medicament of traditional Chinese medicine consists of Abelmoschus manihot” NCT02231125 ↗ |
| Route | Oral | “huangkui capsule are given orally at 2.5 g three times per day” NCT02231138 ↗ |